Opening Ceremony at SOLACI-CACI 2017 Congress

The largest Interventional Cardiology Congress in Latin America has already started. At Pacífico Room, Hilton Buenos Aires Hotel, the Scientific and Organizing Committee presented the objectives and contents for the next three intense days of scientific activity.

Opening Ceremony at SOLACI-CACI 2017 Congress
The first Congress activity was an international joint session with TCT.

The first Congress session was an international joint session with TCT.

 

Congress President Dr. Ruben Piraino highlighted the registration record of over 3000 attendees from all over the world. He also mentioned the 450 faculty members (425 from Latin America and 25 international guests) involved in the event and the 10 live cases, the 8 edited cases, round tables, lunch symposiums, and more, as the main attractions in this “unforgettable event.”

 

Dr. Fernando Cura and Dr. Alberto Sampaolesi (from the Scientific Committee) talked about a “need for a different kind of event, given the disparateness within the scientific audience, composed by both novice professionals and true experts in the field.” They also emphasized the crucial support received from the industry, without which no event of this magnitude could have been pulled off. Furthermore, they expressed their hope that “this work will result in growth for this specialty in this geographical region, higher benefits for patients, and, above all, an increase in the quality of cardiovascular health.”

 

SOLACI President Dr. Ricardo Lluberas mentioned that “the work carried out by the Scientific and Organizing Committee throughout this year was absolutely self-sacrificing. In consequence, once this Congress is over and we return to our homes, we will surely bring with us satisfaction derived from the fact that SOLACI-CACI 2017 will have effectively contributed to the strengthening of interventional cardiology in Latin America.”


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Guatemala Sessions 2026 – Young Interventional Cardiologists Contest – Submit Your Case

The call for applications to participate in the Young Interventional Cardiologists Competition at the Guatemala 2026 Regional Sessions is now open. The event will...

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Watch Again: Clinical Implications of Structural Heart Interventions — TAVI and MitraClip in Daily Practice

The recording of the webinar “Structural Interventions: TAVI and MitraClip in Daily Practice” is now available on the SOLACI YouTube channel. The activity was...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...